reports
- Hybridan Team
- Jon Levinson
Hybridan Research: Sareum Holdings plc
Progress is reported on Sareum’s most advanced assets which are the foundation of its near-term clinical strategy and development priorities. The October 2024 and March 2025 funding enables both simultaneous pipeline work, as well as new opportunities in the constantly evolving therapeutic landscape for kinase inhibitors. Preclinical studies have been carried out to evaluate the potential of the TYK2/JAK1 inhibitors for autoimmune diseases in central nervous system indications (CNS). The study ...
- Hybridan Team
Hybridan Small Cap Feast: 28/04/2025
Our daily digest of news from UK Small Caps 28th April 2025 @HybridanLLP * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Dish of the day Admissions: Last Friday (25th April), The Smarter Web Company (AQSE:SWC), announced its first day of dealings on the on the Aquis Stock Exchange. Th...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 26/03/2025
Our daily digest of news from UK Small Caps @HybridanLLP 26th March 2025 * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: None Delistings: None Yester...
- Hybridan Team
- Jon Levinson
Hybridan Research: Sareum Holdings plc: Upping the Pace
The Interims to December 2024 reported cash of £4.1m, excluding the £1.1m raised in March 2025 at 12.5p. There is a loss before tax reduced to £1.33m, compared to a loss of £2.5m (H123 to end Dec 2023) which included Phase 1a clinical trial costs. There are significant operational highlights in the development pipeline with SDC-1801, SRA737 and SDC-1802 as Sareum advances the next generation of kinase inhibitors for autoimmune disease and cancer. Kinase inhibitors block a type of enzyme called ...
- Hybridan Team
- Jon Levinson
Sareum Holdings PLC 13 March 2025
The licence for SRA737 became available following the programme's return from a US-based biopharma company. As from December 2024, the licence reverted to the CRT Pioneer Fund (CPF). Sareum has now acquired this licence, and the economic terms have been renegotiated, so Sareum will receive a net 63.5% of all future revenues, up from 27.5%. The remaining interests are divided between CPF and Cancer Research Technology, the commercialisation arm of Cancer Research UK. SRA737 is a clinical-stage ...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 13/03/2025
Our daily digest of news from UK Small Caps Our daily digest of news from UK Small Caps @HybridanLLP 13th March 2025 * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the d...
- Brian Moretta
- Mark Thomas
- Martin Hall
Hardman & Co Monthly: January 2025
Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
ARBB ARBUTHNOT BANKING GROUP
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
ACSO ACCESSO TECHNOLOGY GROUP
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
VTAS VOLTA FINANCE (GBP)
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
CSN CHESNARA PLC
SNG SYNAIRGEN PLC
IPO IP GROUP
HAT H&T GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
A0MXLB NB PRIVATE EQUITY PARTNERS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
TISSUE REGENIX GROUP PLC
- Martin Hall
Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
SNG SYNAIRGEN PLC
IPO IP GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
TXG 10X GENOMICS INC CLASS A
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
Z29 TISSUE REGENIX GROUP PLC
029 GROUP SE
- Sean Conroy
Sareum Holdings - SDC-1801 prepping to enter Phase II
Sareum Holdings’ FY24 results summarised an active period for lead asset SDC-1801, a dual TYK2/JAK1 inhibitor, which successfully completed Phase I trials in Australia and is now undergoing preparatory work to commence Phase II studies, likely in psoriasis patients. The recently reported unblinded data noted robust pharmacokinetic (PK)/pharmacodynamic (PD) properties and reiterated the drug’s desirable safety profile. While Sareum had previously proposed a smaller Phase Ib study, the plan has pi...
Hybridan Research 29/10/2024 - Sareum: Increasing chance of success
The Finals to June 2024 reported increased operating losses at £4.6m (FY23:£4.0m),mainly reflecting the continued higher level of R&D investment which successfully completed the Phase 1 clinical trial of SDC1801, its lead candidate, in the autoimmune disease programme. The next development stages could be less costly as no clinical trials are currently scheduled, we therefore anticipate a reduced operating loss for June 2025 with net cash of c. £1.9m. The focus remains on developing the next gen...
Hybridan Small Cap Feast - 21 October 2024
21st October 2024 * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: Pulsar Helium (PLSR.L) announced its First Day of Dealings on AIM on Friday 18th October. The Admission follows the completion of the fundraising of £3.875m...
- Sean Conroy
Sareum Holdings - New funding extends runway to Phase II
Sareum Holdings has announced the completion of a £2.4m private placement and receipt of another A$1.9m (c £1m) in R&D tax credits from Australian authorities, related to the Phase I clinical trial for its lead asset SDC-1801, a next-generation TYK2/JAK1 kinase inhibitor. Management expects the combined funds to support preparatory activities, including longer-term toxicology studies, as the candidate advances towards Phase II trials in psoriasis patients. As a reminder, the company had presente...
Hybridan Research 17/09/2024 - Sareum Holdings: First patent protectin...
Sareum announces it has received a Notice of Allowance from the China National Intellectual Property Administration for Crystalline Forms of SDC- 1801. This is the first patent protecting these crystalline forms in any territory and it’s likely that Japan, the US and European territories will follow. This Chinese Patent is expected to be granted by the end of 2024 and will provide significant protection on several crystalline forms of SDC-1801 and in the method of their application. It builds ...
Hybridan Small Cap Feast - 16 September 2024
16th September 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: Vector Capital (VCAP.L) has delisted from AIM What’s baking in the oven? Our daily digest of news from UK Small Caps If you would like to unsubscribe, please email with “unsubscribe me”. Hybridan Chefs Banquet Buffet*** Acuity...
- Emily Liu
Hybridan Research 02/09/2024 - Sareum Holdings: US patent allowance fo...
Sareum today announced that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent on SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases. The US patent, application number US2021387981, will offer substantial protection on the chemical structure of SDC-1801 and an analogue (a compound that is not identical but similar to the chemical structure of 1801), their use in treating inf...
- Emily Liu
Hybridan Small Cap Feast - 2 September 2024
2nd September 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: St Mark Homes (AQSE: SMAP) has delisted from the AQSE Growth Market. East Imperial Plc (EISB.L) has delisted from the Main Market. ReNeuron Group (RENE.L) has delisted from AIM. Infrastructure India Plc (IIP.L) has delisted from AI...
- Emily Liu
Hybridan Small Cap Feast 10 July 2024
Dish of the day Admissions: Delistings: Gresham Technologies (GHT.L) has delisted from AIM Partway Group (PTY.L) delisted from the Main market yesterday What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 8th July 2024: Rome Resources: The Canada-based early-stage resource exploration Company has announced its intention to IPO on AIM in order to continue to make financial progress on its “Bisie North Tin Project”. The Company’s first day of trading on AIM is exp...
- Emily Liu
Hybridan Small Cap Feast - 02/07/24 - Sareum Holdings: Positive topli...
Sareum announced positive topline data from its Phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases. Sareum believes that dual TYK2/JAK1 inhibition offers the potential for increased efficacy in psoriasis, compared with existing approved oral therapies. The results are summarised as follows: • Blood plasma levels of SDC-1801 significantly in excess of the predicted therapeutic exposure were achie...
- Sean Conroy
Sareum Holdings - SDC-1801 records positive Phase Ia data
Sareum Holdings has announced positive top-line data from the Phase Ia clinical trial for SDC-1801, its lead asset, a novel TYK2/JAK1 inhibitor targeting autoimmune conditions. The results, which include data from the multiple ascending dose (MAD) arm, reiterate the drug-supportive safety profile and once-daily dosing potential, complementing the preliminary data released in February 2024. Notably, no significant change in serum creatinine levels (which tends to affect kidney function) was obser...
Hybridan Small Cap Feast - 1 July 2024
1 July 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: Delistings: San Leon Energy (SLE.L) has delisted from AIM Gensource Potash Corporation (GSP.L) has delisted from AIM What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 19 June 2024: IntelliAM, an artificial intelligence c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.